


INTERNATIONAL EDITION

Not authorised for sale in United States, Canada, Australia, New Zealand, Puerto Rico or the U.S. Virgin Islands.

Ansel's

Pharmaceutical Dosage Forms and Drug Delivery Systems

ELEVENTH EDITION



Loyd V. Allen, Jr.



Wolters Kluwer



Wolters Kluwer

CONTENTS

Preface v

Acknowledgments vii

List of Physical Pharmacy Capsules x

SECTION I. Introduction to Drugs, Drug Dosage Forms, and Drug Delivery Systems 1

- 1** Introduction to Drugs and Pharmacy 2
- 2** New Drug Development and Approval Process 26
- 3** Current Good Manufacturing Practices and Current Good Compounding Practices 57

SECTION II. Drug Dosage Form and Drug Delivery System Design 75

- 4** Dosage Form Design: Pharmaceutica and Formulation Considerations 76
- 5** Dosage Form Design: Biopharmaceutical and Pharmacokinetic Considerations 127

SECTION III. Solid Dosage Forms and Solid Modified-Release Drug Delivery Systems 163

- 6** Powders and Granules 164
- 7** Capsules 186
- 8** Tablets 203
- 9** Solid Oral Modified Release Dosage Forms and Drug Delivery Systems 230

SECTION IV. Semisolid Dosage Forms and Transdermal Systems 243

- 10** Ointments, Creams, and Gels 244
- 11** Transdermals and Transdermal Drug Delivery Systems 268

SECTION V. Suppositories, Inserts, and Sticks 285

- 12** Suppositories, Inserts, and Sticks 286

SECTION VI. Liquid Dosage Forms 309

- 13** Solutions 310
- 14** Disperse Systems 347

SECTION VII. Sterile Dosage Forms and Delivery Systems 395

- 15** Parenterals 396
- 16** Biologics 444
- 17** Special Solutions and Suspensions 464

SECTION VIII. Novel and Advanced Dosage Forms, Delivery Systems, and Devices 487

- 18** Radiopharmaceuticals 488
- 19** Products of Biotechnology 513
- 20** Novel Dosage Forms and Drug Delivery Technologies 550
- 21** Clinical Pharmaceutics 570

Appendices

- A** Definitions of Selected Drug Categories 585
- B** Glossary of Pharmaceutical Terms and Dosage Forms 594
- C** Systems and Techniques of Pharmaceutical Measurement 600

LIST OF PHYSICAL PHARMACY CAPSULES

- | | | | | | |
|-------------|---|-----|-------------|--|-----|
| 4.1 | Heat of Vaporization | 82 | 6.2 | Particle Size Reduction | 170 |
| 4.2 | Melting Point Depression | 83 | 6.3 | Effervescent Granules | 181 |
| 4.3 | The Phase Rule | 84 | 10.1 | Clinical Pharmaceutics—The Blurred Line Between “Topical” and “Transderma” | 251 |
| 4.4 | Triangular (Three-component) Phase Diagram | 85 | 10.2 | Clinical Pharmaceutics—Quantity to Apply, Skin Types, and Thermodynamic Properties | 256 |
| 4.5 | Solubility and Particle Size | 86 | 10.3 | Clinical Pharmaceutics—“Formulating for Successful Transdermal/Topical Delivery” | 263 |
| 4.6 | Principles of pH | 87 | 10.4 | Clinical Pharmaceutics—“Dilution of Creams and Gels” | 264 |
| 4.7 | Solubility and pH | 88 | 11.1 | Formulating for Successful Transdermal/Topical Delivery | 275 |
| 4.8 | Fick Laws of Diffusion and the Noyes–Whitney Equation | 90 | 12.1 | Density (Dose Replacement) Calculations for Suppositories | 297 |
| 4.9 | Partition Coefficient | 93 | 13.1 | Preservation of Syrups | 327 |
| 4.10 | pK _a /Dissociation Constants | 95 | 14.1 | Particles Versus Molecules | 348 |
| 4.11 | Hydrates and Solvates | 96 | 14.2 | Sedimentation Rate and Stokes Equation | 349 |
| 4.12 | Organic Salts | 98 | 14.3 | Rheology | 352 |
| 4.13 | Organic Esters | 99 | 14.4 | Gibbs Free Energy in an Emulsion | 365 |
| 4.14 | Potency-Designated Active Pharmaceutical Ingredients | 100 | 14.5 | Blending of Surfactants | 367 |
| 4.15 | Complex Organic Molecules | 101 | 14.6 | Surface Area of Globules | 368 |
| 4.16 | Rate Reactions | 104 | 14.7 | Partial Pressure and Aerosol Formulation | 381 |
| 4.17 | Buffer Capacity | 106 | 15.1 | Colligative Properties of Drugs | 403 |
| 4.18 | Analytical Methods and Standard Curves | 109 | 15.2 | Endotoxin Calculations | 411 |
| 4.19 | Q ₁₀ Method of Shelf Life Estimation | 118 | 17.1 | pH and Solubility | 469 |
| 5.1 | Particle Size, Surface Area, and Dissolution Rate | 133 | | | |
| 6.1 | Micromeritics | 166 | | | |